Allergan, Inc. and Medytox, Inc. have entered into a license agreement under which Allergan gains exclusive worldwide rights, outside of Korea, to develop and commercialize certain neurotoxin product candidates currently in development, including a potential liquid-injectable product.   Allergan will pay $65 million upfront and make additional payments of as much as $116.5 million based on certain development milestones, and as much as $180.5 million for certain commercialization milestones, and...